[go: up one dir, main page]

US20160176883A1 - Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor - Google Patents

Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor Download PDF

Info

Publication number
US20160176883A1
US20160176883A1 US15/018,953 US201615018953A US2016176883A1 US 20160176883 A1 US20160176883 A1 US 20160176883A1 US 201615018953 A US201615018953 A US 201615018953A US 2016176883 A1 US2016176883 A1 US 2016176883A1
Authority
US
United States
Prior art keywords
phosphate salt
salt
pyrrolo
dihydro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/018,953
Inventor
Paul Allen Sutton
Eric M. Loeser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47604250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20160176883(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to US15/018,953 priority Critical patent/US20160176883A1/en
Publication of US20160176883A1 publication Critical patent/US20160176883A1/en
Assigned to NOVARTIS PHARMACEUTICALS CORPORATION reassignment NOVARTIS PHARMACEUTICALS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOESER, ERIC M, SUTTON, PAUL ALLEN
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS PHARMACEUTICALS CORPORATION
Assigned to RECORDATI AG reassignment RECORDATI AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS AG
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Definitions

  • the present invention relates to specific salts and salt forms of 4-(R)-(6,7-Dihydro-6H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile (also referred to as “Compound A” within this application), these salts and salt forms for use in methods of treatment of diseases and conditions, the use of these salts and salt forms in the manufacture of medicaments for the treatment of diseases and conditions, methods of treatment comprising administering said salts or salt forms to a mammal in need thereof in therapeutically effective amounts for treating a disease of condition affecting said mammal, pharmaceutical formulations comprising said salts or salt forms.
  • Compound A in the form of free base has a quit low melting point of about 111.5° C. which constitutes a certain risk regarding physical stability of the compound during manufacture, storage and processing to pharmaceutical formulations. Thus there was a need to find specific processing conditions or specific forms of this compound that allow for stable processing.
  • salt of Compound A Surprisingly it was difficult to obtain salt of Compound A. About 20 various different salt forming agents were evaluated with Compound A, but only 3 salts were formed phosphate salt, nitrate salt and hydrochloride sat. Other salt forming agents did not produce solid material at al or not in any useful quantity or quality.
  • the phosphate salt shows the most superior properties. It can be isolated and manufactured better and thus is advantageous over the free base compound, with additional properties such as a higher melting point over the free base and other salts, lower hygroscopicity and Improved aqueous solubility.
  • the nitrate salt also shows comparable advantages.
  • the invention in a first aspect, relates to a phosphate salt of Compound A, especially in crystalline forms, particularly in crystalline Form A as described below.
  • phosphate salt refers to the acid addition salt of compound A with phosphoric acid. More particularly. It refers to the dihydrogenphosphate of compound A protonated once, that is, wherein compound A is protonated once and thus each molecule carries a single positive charge, while the counterion is H 2 PO ⁇ ).
  • the second aspect of the invention relates to a nitrate salt of Compound A, especially in crystalline forms.
  • the invention relates to the salts or salt forms mentioned herein in the manufacture of medicaments for the treatment of diseases and conditions, to said salts or salt forms (especially in the form of pharmaceutical compositions) for use in the treatment of diseases and conditions, to methods of treatment comprising administering said salts or salt forms to a mammal in need thereof in therapeutically effective amounts for treating a disease of condition affecting said mammal, pharmaceutical formulations comprising said salts or salt forms.
  • the invention relates to a pharmaceutical composition that includes (an especially prophylactically or therapeutically effective amount of) a phosphate salt of Compound A and one or more pharmaceutically acceptable excipients, in particular for use in the treatment of conditions or diseases described herein, especially conditions or diseases mediated by aldosterone synthase or aromatase.
  • the pharmaceutical compositions of this aspect of the invention may be formulated, e.g., for oral administration.
  • the invention provides a process for making a nitrate salt or a phosphate salt, especially in crystalline form, respectively, of Compound A, the process comprising:
  • Variants of this process are provided and included as embodiments of the invention, e.g. in which seed crystals of the respective nitrate salt or phosphate salt of Compound A are added, the solvent is at least partially removed (e.g. by evaporation), the temperature is lowered to improve crystallization or on which anti-solvents are added to improve precipitation, or any combinations of such process measures.
  • This process may also be a step (e.g. the final purification step) in the manufacture of the respective salt, e.g. at the end of the process described for the manufacture of the free base in WO 20071024945 A1, and the corresponding general method of manufacture is incorporated by reference herein and applied specifically to the preparation of the compound Compound A.
  • Forms B, C, D, E, F, G and H of the phosphate salt may be obtained e.g. as described in the Examples, where the temperature is room temperature (23° C.) ⁇ 10° C. and the solvents may be replaced by corresponding solvents.
  • the invention relates to a phosphate salt of Compound A, in particular with a molar ratio of Compound A to phosphate of about 1:1, in particular in crystalline form.
  • the invention relates to a crystalline phosphate salt of Compound A having a melting point that is at least 50° C., at least 55° C. or at least 85° C. higher than that of the free base.
  • the phosphate salt of Compound A has a melting temperature of at least 170° C. or at least 197° C.
  • the phosphate salt of Compound A has a melting temperature between 205° C. to 214° C., between 206° C. to 213° C., between 208° C. to 213° C., between 209° C. to 212° C. or between 209° C. to 211° C.
  • TG/DTA thermogravimetry/differential thermal analysis
  • the invention relates to “Form A” of the crystalline phosphate salt of Compound A, especially with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16 or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 6.0 , 10.0, 12.1, 12.9 , 14.0, 14.5, 15.5 , 16.0 , 16.3 , 17.5, 18.2, 18.4, 19.7 , 20.4 , 22.1 , 24.3 , 29.2 with the underlined peaks defining a preferred embodiment and all peaks defining a more preferred embodiment.
  • the ‘Form A’ of the crystalline phosphate salt of Compound A has a melting temperature of 210 ⁇ 5° C., 210 ⁇ 2° C., 210 ⁇ 1° C. or 210 ⁇ 0.5° C. or 210.2° C.
  • the invention relates to Form A with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 6.0, 12.9, 15.5, 18.0, 16.3, 19.7, 20.4, 22.1, 24.3, 29.2.
  • the two largest peaks of Form A in the XRPD diagram have a relative intensity of 1 to 0.5 to 0.7, especially of 1 to 0.55 to 0.65, more especially of 0.57 to 0.61, e.g. of 1 to 0.59 (obtainable by integration of each of the peaks in the XRPD diagrams).
  • the larger peek is at a 2-theta ( ⁇ ) value of 6.0 ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees and the smaller peak at a 2-theta ( ⁇ ) value of 19.7 ⁇ 1 or ⁇ 0.5, in particular a 0.2 degrees, respectively.
  • Another embodiment relates to form A with an XRPD showing at least one or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 12.9 16.3 and 20.4 degrees.
  • Preferred is the phosphate salt showing an XRPD as shown in FIG. 1 -A.
  • a specific embodiment of the invention relates to “Form A” of the crystalline phosphate salt of Compound A, having a melting point between 209 and 212° C.
  • the invention relates to a “Form B” of crystalline phosphate salt of Compound A with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18 or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peek may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 02 degrees: 6.0, 9.8, 11.8 , 12.7, 12.9, 14.0, 14.3, 15.2 , 16.0, 16.3, 17.5, 18.0, 18.4, 19.3 , 19.7, 20.1, 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form B showing an XRPD as shown in FIG. 1 -B.
  • An embodiment of the invention relates to Form B of the crystalline phosphate salt of Compound A, having a melting point of 209 ⁇ 5° C., for example between 207 and 211° C., e.g. of 209.0° C.
  • the Invention relates to a “Form C” of crystalline phosphate sat of Compound A with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17 or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degree: 6.0, 10.0, 11.9 , 12.9, 14.0, 14.5, 15.5, 16.0, 16.3, 17.8 , 18.2, 18.4, 19.3 , 19.7, 20.1 , 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form C showing an XRPD as shown in FIG. 1 -C.
  • An embodiment of the invention relates to “Form C” of the crystalline phosphate salt of Compound A, having a melting point of 191 ⁇ 5° C., for example between 189 and 193° C., e.g. of 190.7° C.
  • the invention relates to a “Form D” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17 or al of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 6.2, 10.0, 12.4 , 12.9, 13.3 , 14.8 , 15.5, 16.0, 16.6 , 17.5, 18.2, 18.4, 19.3 , 19.7, 20.2, 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, al peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form D showing an XRPD as shown in FIG. 1 -D.
  • An embodiment of the invention relates to “Form D” of the crystalline phosphate salt of Compound A, having a melting point of 211 ⁇ 5° C., for example between 208 and 213° C., e.g. of 210.8° C.
  • the invention relates to a “Form E” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17 or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 6.4 , 10.3, 12.1, 12.9, 13.3, 14.5, 15.2, 16.0, 16.8 , 17.5, 18.2, 18.4, 19.3 , 19.7, 20.1 , 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form E showing an XRPD as shown in FIG. 1 -E.
  • An embodiment of the invention relates to “Form E” of the crystalline phosphate salt of Compound A, having a melting point of 214 ⁇ 5° C., for example between 211 and 216° C., e.g. of 213.6° C.
  • the Invention relates to a “Form F” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 18, 17 or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 6.0, 10.0, 12.1, 12.9, 13.8 , 14.0, 15.5, 16.0, 16.6 , 17.5, 18.2, 18.4, 19.1 , 19.7, 20.1 , 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form F showing an XRPD as shown in FIG. 1 -F.
  • An embodiment of the invention relates to “Form F” of the crystalline phosphate salt of Compound A, having a melting point of 201 ⁇ 5° C., for example between 199 and 203° C., e.g. of 201.1° C.
  • the invention relates to a “Form G” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) value, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 6.0, 12.1, 13.1, 14.0, 14.5, 15.5, 15.8, 16.3, 17.5, 18.2, 18.4, 19.3 , 19.7, 20.1 , 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form G showing an XRPD as shown in FIG. 1 -G.
  • An embodiment of the invention relates to “Form G” of the crystalline phosphate salt of Compound A, having a maelting point of 180 ⁇ 5° C., for example between 177 and 183° C., e.g. of 179.8° C.
  • the invention relates to a “Form H” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, or al of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 6.0, 10.2, 12.1, 13.1, 14.0, 14.5, 15.5, 16.2, 16.5, 17.5, 18.2, 18.4, 19.3 , 19.7, 20.1 , 22.2, 24.3, 29.5, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form H showing an XRPD as shown in FIG. 1 -H.
  • An embodiment of the invention relates to “Form H” of the crystalline phosphate salt of Compound A, having a melting point of 208 ⁇ 5° C., for example between 206 and 210° C., e.g. of 208.0° C.
  • the invention relates to a nitrate salt of Compound A.
  • a nitrate salt of Compound A In particular with a molar ratio of Compound A to nitrate of about 1:1, in particular in crystalline form.
  • the invention relates to a crystalline nitrate salt of Compound A having a melting point that is at least 40° C. higher than that of the free base, especially (using TG/DTA as described above) between 160 and 163° C.
  • the invention relates to a crystalline nitrate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17 or all of the following peaks, given as angle of refraction 2-theta ( ⁇ ) values, obtainable as described in the Examples, where each peak may vary by ⁇ 1 or ⁇ 0.5, in particular ⁇ 0.2 degrees: 7.4 , 10.6, 12.5, 15.0 , 15.7, 17.5, 18.0 , 18.7 , 20.4 , 21.2 , 22.8, 24.6, 26.5, 28.2 , 28.8, 29.9, 31.0, 31.5, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment.
  • Preferred is the nitrate salt showing an XRPD as shown in FIG. 2 .
  • a specific embodiment of the invention relates to a crystalline nitrate salt of Compound A showing the XRPD characteristics above and a melting point between 180 and 163° C. using TG/DTA.
  • the compound 6,7-dihydro-5H-pyrrolo[1,2-c]imidazo-6-yl-3-fluoro-benzonitrile as free base) and especially its enantiomers, especially 4-(R)-(6,7-dihydro-6H-pyrrolo[1,2-c]imidazol-yl)-3-fluoro-benzonitrile, can be manufactured as described in published international patent application WO 2007/024945 which is incorporated by reference herein (see especially Table 2, and Chiral Resolution on page 87, F. 5).
  • “Prophylactically or therapeutically effective amount” means the amount of a compound that, when administered for treating or preventing a disease or disorder mentioned above or below, is sufficient to effect such treatment or prevention for the disease or disorder, prophylactic especially refers to the prevention of the onset or recurrence or ameliorating the onset or recurrence of such disease or disorder, therapeutic especially refers to the amelioration or complete suppression of one or more symptoms up to the cure of such disease or disorder.
  • the “prophylactically or therapeutically effective amount” will vary depending on the salt(s) or salt form(s) used, the disease or disorder and its severity and the age, weight, etc., of the patient to be treated.
  • composition is intended to encompass a product comprising the active ingredient(s), optionally at least one pharmaceutically acceptable excipients.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing the active ingredient, additional active ingredient(s) and pharmaceutically acceptable excepients.
  • composition is also intended to comprise a combination product, comprising a salt or salt form according to any one of claims 1 to 12 , in combination with one or more other therapeutic agents (pharmaceutically active compounds) and preferably at least one pharmaceutically acceptable excipient.
  • therapeutic agents include at least one or two or more selected from the following groups:
  • Such compounds are e.g. defined in WO 2007/024945 A1 and are included here by reference.
  • the therapeutic agent(s) may be in the free (non-salt) form or in the form of a pharmaceutically acceptable salt, respectively.
  • a compound of the present invention may be administered either simultaneously, before or after the other therapeutic agent (active ingredient), either separately by the same or different route of administration or together in the same pharmaceutical formulation.
  • the combination product may comprise the salt or salt form according to the invention in one, one or more other therapeutic agents in a separate formulation, but in the form of a kit of parts for the simultaneous or chronically staggered administration, or in one fixed combination.
  • simultaneous administration can take place in the form of one fixed combination with two or three or more active ingredients, or by simultaneously administering two or three or more compounds that are formulated independently.
  • Sequential administration preferably means administration of one (or more) compounds or active ingredients of a combination at one time point, other compounds or active ingredients at a different time point, that is, in a chronically staggered manner, preferably such that the combination shows more efficiency then the single compounds administered independently (especially showing synergism).
  • Separate administration preferably means administration of the compounds or active ingredients of the combination independently of each other at different time points, preferably meaning that two, or three or more compounds are administered such that no overlap of measurable blood levels of both compounds are present in an overlapping manner (at the same time).
  • combinations of two or three or more of sequential, separate and simultaneous administrations are possible, preferably such that the combination compound-drugs show a joint therapeutic effect that exceeds the effect found when the combination compound-drugs are used independently at time intervals so large that no mutual effect on their therapeutic efficiency can be found, a synergistic effect being especially preferred.
  • the pharmaceutical compositions contain a therapeutically effective amount of a salt or salt form of Compound A of the invention as defined above or below, either alone or in a combination with one or more therapeutic agents, e.g., each at an effective therapeutic dose as reported in the art, selected from the group consisting of an antiestrogen; an antiandrogen, a gonadorelin agonist a topoisomerase I inhibitor; a topoisomerase II inhibitor a microtubule active agent an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a compound targeting/decreasing a protein or lipid kinase activity or a protein or lipid phosphatase activity, a anti-angiogenic compound; a compound which induces cell differentiation processes; monoclonal antibodies; a cyclooxygenase inhibitor; a bisphosphonate; a heparanase inhibitor a biological response modifier; an inhibitor of Ras oncogenic isoforms;
  • the present invention provides:
  • the salt(s) or salt form(s) of the present invention are useful as aldosterone synthase inhibitors (see e.g. WO 2007/024945 incorporated by reference herein regarding the diseases and disorders related to aldosterone synthase).
  • the salt(s) or salt form(s) of the present invention as aldosterone synthase inhibitors are useful for treatment of a disorder or disease characterized by abnormal aldosterone synthase activity.
  • the salt(s) or salt form(s) of the present invention are also useful for treatment of a disorder or disease selected from hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, sleep apnoea, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction.
  • a disorder or disease selected from hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, sleep apnoea, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endo
  • the disorder or disease to be treated with a salt or salt form according to the inventions is especially selected from hypertension (essential or resistant), primary aldosteronism congestive heart failure and acute heart failure.
  • diseases or disorders of specific interest are selected from the group consisting of heart failure, cachexia, acute coronary syndrome, chronic stress syndrome, Cushing's disease, Cushing's syndrome, metabolic syndrome or hypercortisolemaia.
  • the disease is Cushing's disease
  • “Protic or an aprotic solvents” may be selected from aqueous or non-aqueous solvents or solvent mixtures, e.g. comprising one or more selected from water, C 1-7 alkanols, C 1-8 ketones, C 1-7 alkanediols, C 1-7 alkylnitriles, C 1-7 alkyl-C 2-7 alkanoates, with methanol, acetone, propylene glykol, ethyl acetate, or especially ethanol being especially preferred.
  • Anti-solvent is a solvent which when added to an existing solution of a substance reduces the solubility of the substance.
  • anti-solvents are especially less polar (more hydrophilic) solvents than those used for dissolving Compound A before the addition of nitric acid or phosphoric acid, e.g. organic solvents that are at least to a certain extent (e.g. at east up to 10 vol %) miscible with water.
  • FIG. 1 -A shows the X-ray powder diffraction pattern of the initial phosphate salt Form A.
  • FIG. 1 -B shows the X-ray powder diffraction pattern of phosphate salt Form B.
  • FIG. 1 -C shows the X-ray powder diffraction pattern of phosphate salt Form C.
  • FIG. 1 -D shows the X-ray powder diffraction pattern of phosphate salt Form D.
  • FIG. 1 -E shows the X-ray powder diffraction pattern of phosphate salt Form E.
  • FIG. 1 -F shows the X-ray powder diffraction pattern of phosphate salt Form F.
  • FIG. 1 -G shows the X-ray powder diffraction pattern of phosphate salt Form G.
  • FIG. 1 -H shows the X-ray powder diffraction pattern of phosphate salt Form H.
  • FIG. 2 shows the X-ray powder diffraction pattern of nitrate salt.
  • FIG. 3 shows the X-ray powder diffraction pattern of chloride salt.
  • al reactions are carried out at room temperature (21 to 24° C., e.g. 23° C.).
  • the molar ratio of phosphate to 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-fluoro-benzonitrile in the obtained salt is 1:1.
  • the phosphate salt was soluble at the 0.1% target concentration and stable for 2 days at 50° C.
  • the free base remained largely insoluble. It converted from a free flowing solid into an oily material within a short time after contact with water, and remained as such for the 2 day period at 50° C.
  • Sorption/desorption isotherms were measured using the VTI 100 humidity microbalance (VTI Corporation, Hialeah, Fla., USA). Measurements were carried out at 25° C. Samples were dried under N 2 flow at 25° C.
  • the hygroscopicity of the phosphate salt was found to be only 0% water uptake at 5% RH and 0.9% water uptake at 75% relative humidity.
  • solubility of the phosphate salt is comparably low in non-aqueous solvents which are thus anti-solvents for the salt, thus making it possible to achieve good precipitation and thus good yields and good purity.
  • solubility in water is better than that for the free base which is advantageous for providing oral or parenteral formulations.
  • the melting point was determined by TG/DTA as described above and was determined to be 210.2° C.
  • the resulting 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile nitrate salt has a 1:1 molar ratio of base to chloride. It shows the XRPD represented in FIG. 2 .
  • the hygroscopicity (measured under the conditions mentioned in Example 1) of the nitrate salt of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile was found to be 0% water uptake at 5% RH and 0.2% at 75% RH.
  • the nitrate salt was soluble at the 0.1% target concentration and stable for 2 days at 50° C.
  • the free base remained largely insoluble. It converted from a free flowing solid into an oily material within a short time after contact with water, and remained as such for the 2 day period at 50° C.
  • the melting point of the nitrate was determined to be between 160 and 163° C.
  • Form A of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazo-5-yl)-3-fluoro-benzonitrile phosphate salt was equilibrated in IPA for 72 hours at 50° C. Sample was collected by filtration and allowed to air dry. A melting temperature of form B of 209.0° C. was determined by TG/DTA.
  • Table 3-1 shows the angle of refraction 2-Theta values (in degrees) for the XRDPs of FIGS. 1 -A to 1 -H for Forms A to G in comparison to those for Form A, with characteristic peaks for each form in comparison to Form A being underlined:
  • the HCl salt showed excessive hygroscopicity, as is shown in the following table:
  • Moisture gain (%) comparison between forms (r.h. relative humidity) r.h. % free base Nitrate Phosphate HCl 0 0.0 0.0 0.0 0.0 5 0.0 0.0 0.0 0.0 25 0.1 0.1 0.1 0.5 50 0.2 0.2 0.1 0.2 75 0.3 0.2 0.2 0.2 85 0.5 0.2 0.3 3.3 95 1.0 0.2 0.8 23.6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to a phosphate salt or a nitrate salt of 4-(R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile, especially in crystalline form, and specific forms of these salts, as well as related invention embodiments. The salts and salt forms allow for the prophylactic and/or therapeutic treatment of aldosterone synthase and/or aromatase mediated diseases or disorders.

Description

    SUMMARY OF THE INVENTION
  • The present invention relates to specific salts and salt forms of 4-(R)-(6,7-Dihydro-6H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile (also referred to as “Compound A” within this application), these salts and salt forms for use in methods of treatment of diseases and conditions, the use of these salts and salt forms in the manufacture of medicaments for the treatment of diseases and conditions, methods of treatment comprising administering said salts or salt forms to a mammal in need thereof in therapeutically effective amounts for treating a disease of condition affecting said mammal, pharmaceutical formulations comprising said salts or salt forms.
    • BACKGROUND OF THE INVENTION
  • The compound 6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-yl-3-fluoro-benzonitrile, its 4-(R)-enantiomer with formula (I)
  • Figure US20160176883A1-20160623-C00001
  • and its manufacture are described in WO 2007/024945 A1, among many other compounds disclosed therein. It is known to be active as inhibitor of aldosterone synthase and aromatase.
  • For example, in a clinical proof-of-concept study in patients with primary aldosteronism efficiency of 4-(R)-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile free base in inhibition of aldosterone synthase could be shown (see e.g., Amar L. et al., Hypertension (5), 831-838 November 2010 (Epub 2010 September).
  • No specific salts of the compounds mentioned in said patent application are disclosed.
  • Compound A in the form of free base has a quit low melting point of about 111.5° C. which constitutes a certain risk regarding physical stability of the compound during manufacture, storage and processing to pharmaceutical formulations. Thus there was a need to find specific processing conditions or specific forms of this compound that allow for stable processing.
    • GENERAL DESCRIPTION OF THE INVENTION
  • Surprisingly it was difficult to obtain salt of Compound A. About 20 various different salt forming agents were evaluated with Compound A, but only 3 salts were formed phosphate salt, nitrate salt and hydrochloride sat. Other salt forming agents did not produce solid material at al or not in any useful quantity or quality.
  • The phosphate salt shows the most superior properties. It can be isolated and manufactured better and thus is advantageous over the free base compound, with additional properties such as a higher melting point over the free base and other salts, lower hygroscopicity and Improved aqueous solubility. The nitrate salt also shows comparable advantages.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The invention, in a first aspect, relates to a phosphate salt of Compound A, especially in crystalline forms, particularly in crystalline Form A as described below.
  • The term “phosphate salt” as used in the present application, refers to the acid addition salt of compound A with phosphoric acid. More particularly. It refers to the dihydrogenphosphate of compound A protonated once, that is, wherein compound A is protonated once and thus each molecule carries a single positive charge, while the counterion is H2PO−).
  • The second aspect of the invention relates to a nitrate salt of Compound A, especially in crystalline forms.
  • In further aspects the invention relates to the salts or salt forms mentioned herein in the manufacture of medicaments for the treatment of diseases and conditions, to said salts or salt forms (especially in the form of pharmaceutical compositions) for use in the treatment of diseases and conditions, to methods of treatment comprising administering said salts or salt forms to a mammal in need thereof in therapeutically effective amounts for treating a disease of condition affecting said mammal, pharmaceutical formulations comprising said salts or salt forms.
  • Thus, in one further aspect the invention relates to a pharmaceutical composition that includes (an especially prophylactically or therapeutically effective amount of) a phosphate salt of Compound A and one or more pharmaceutically acceptable excipients, in particular for use in the treatment of conditions or diseases described herein, especially conditions or diseases mediated by aldosterone synthase or aromatase. The pharmaceutical compositions of this aspect of the invention may be formulated, e.g., for oral administration.
  • In accordance with yet another aspect, the invention provides a process for making a nitrate salt or a phosphate salt, especially in crystalline form, respectively, of Compound A, the process comprising:
      • (a) providing a solution of Compound A in either a protic or an aprotic polar solvent, especially in an aqueous-alcoholic or alcoholic solution (alcoholic especially referring to hydroxy-C1-7alkanes) (where said solution may have a temperature in the range e.g. from 0° C. to the boiling point of the solution, e.g. up to 90° C., e.g. In the range from 10 to 50° C.);
      • (b) adding nitric acid or phosphoric acid; and
      • (c) isolating the formed crystalline form of a nitrate salt or a phosphate salt of Compound A;
      • where if desired one obtainable (then educt) salt can be converted into the other salt by addition of the corresponding acid contributing the other anion to a solution of the educt salt.
  • Variants of this process are provided and included as embodiments of the invention, e.g. in which seed crystals of the respective nitrate salt or phosphate salt of Compound A are added, the solvent is at least partially removed (e.g. by evaporation), the temperature is lowered to improve crystallization or on which anti-solvents are added to improve precipitation, or any combinations of such process measures.
  • This process may also be a step (e.g. the final purification step) in the manufacture of the respective salt, e.g. at the end of the process described for the manufacture of the free base in WO 20071024945 A1, and the corresponding general method of manufacture is incorporated by reference herein and applied specifically to the preparation of the compound Compound A.
  • Forms B, C, D, E, F, G and H of the phosphate salt may be obtained e.g. as described in the Examples, where the temperature is room temperature (23° C.)±10° C. and the solvents may be replaced by corresponding solvents.
  • In one first particular embodiment, the invention relates to a phosphate salt of Compound A, in particular with a molar ratio of Compound A to phosphate of about 1:1, in particular in crystalline form.
  • In one special embodiment, the invention relates to a crystalline phosphate salt of Compound A having a melting point that is at least 50° C., at least 55° C. or at least 85° C. higher than that of the free base.
  • In one embodiment, the phosphate salt of Compound A has a melting temperature of at least 170° C. or at least 197° C.
  • In one embodiment, the phosphate salt of Compound A has a melting temperature between 205° C. to 214° C., between 206° C. to 213° C., between 208° C. to 213° C., between 209° C. to 212° C. or between 209° C. to 211° C.
  • The melting temperatures herein, if not described otherwise, are obtained using thermogravimetry/differential thermal analysis (TG/DTA). TG/DTA is determined using a Seiko EXSTAR TG/DTA 6000, temperature range room temperature to 250° C., scan rate 10° C./min, nitrogen flow 100 ml/min.
  • In another special embodiment, the invention relates to “Form A” of the crystalline phosphate salt of Compound A, especially with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16 or all of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 6.0, 10.0, 12.1, 12.9, 14.0, 14.5, 15.5, 16.0, 16.3, 17.5, 18.2, 18.4, 19.7, 20.4, 22.1, 24.3, 29.2 with the underlined peaks defining a preferred embodiment and all peaks defining a more preferred embodiment.
  • In one embodiment, the ‘Form A’ of the crystalline phosphate salt of Compound A has a melting temperature of 210±5° C., 210±2° C., 210±1° C. or 210±0.5° C. or 210.2° C.
  • In one embodiment, the invention relates to Form A with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight or all of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 6.0, 12.9, 15.5, 18.0, 16.3, 19.7, 20.4, 22.1, 24.3, 29.2.
  • In one embodiment, the two largest peaks of Form A in the XRPD diagram have a relative intensity of 1 to 0.5 to 0.7, especially of 1 to 0.55 to 0.65, more especially of 0.57 to 0.61, e.g. of 1 to 0.59 (obtainable by integration of each of the peaks in the XRPD diagrams). In a particular embodiment the larger peek is at a 2-theta (θ) value of 6.0±1 or ±0.5, in particular ±0.2 degrees and the smaller peak at a 2-theta (θ) value of 19.7±1 or ±0.5, in particular a 0.2 degrees, respectively.
  • Another embodiment relates to form A with an XRPD showing at least one or all of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 12.9 16.3 and 20.4 degrees.
  • Preferred is the phosphate salt showing an XRPD as shown in FIG. 1-A.
  • A specific embodiment of the invention relates to “Form A” of the crystalline phosphate salt of Compound A, having a melting point between 209 and 212° C.
  • In one embodiment, the invention relates to a “Form B” of crystalline phosphate salt of Compound A with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18 or all of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peek may vary by ±1 or ±0.5, in particular ±02 degrees: 6.0, 9.8, 11.8, 12.7, 12.9, 14.0, 14.3, 15.2, 16.0, 16.3, 17.5, 18.0, 18.4, 19.3, 19.7, 20.1, 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form B showing an XRPD as shown in FIG. 1-B.
  • An embodiment of the invention relates to Form B of the crystalline phosphate salt of Compound A, having a melting point of 209±5° C., for example between 207 and 211° C., e.g. of 209.0° C.
  • In one embodiment, the Invention relates to a “Form C” of crystalline phosphate sat of Compound A with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17 or all of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degree: 6.0, 10.0, 11.9, 12.9, 14.0, 14.5, 15.5, 16.0, 16.3, 17.8, 18.2, 18.4, 19.3, 19.7, 20.1, 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form C showing an XRPD as shown in FIG. 1-C.
  • An embodiment of the invention relates to “Form C” of the crystalline phosphate salt of Compound A, having a melting point of 191±5° C., for example between 189 and 193° C., e.g. of 190.7° C.
  • In one embodiment, the invention relates to a “Form D” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17 or al of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 6.2, 10.0, 12.4, 12.9, 13.3, 14.8, 15.5, 16.0, 16.6, 17.5, 18.2, 18.4, 19.3, 19.7, 20.2, 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, al peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form D showing an XRPD as shown in FIG. 1-D.
  • An embodiment of the invention relates to “Form D” of the crystalline phosphate salt of Compound A, having a melting point of 211±5° C., for example between 208 and 213° C., e.g. of 210.8° C.
  • In one embodiment, the invention relates to a “Form E” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17 or all of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 6.4, 10.3, 12.1, 12.9, 13.3, 14.5, 15.2, 16.0, 16.8, 17.5, 18.2, 18.4, 19.3, 19.7, 20.1, 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form E showing an XRPD as shown in FIG. 1-E.
  • An embodiment of the invention relates to “Form E” of the crystalline phosphate salt of Compound A, having a melting point of 214±5° C., for example between 211 and 216° C., e.g. of 213.6° C.
  • In one embodiment, the Invention relates to a “Form F” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 18, 17 or all of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 6.0, 10.0, 12.1, 12.9, 13.8, 14.0, 15.5, 16.0, 16.6, 17.5, 18.2, 18.4, 19.1, 19.7, 20.1, 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form F showing an XRPD as shown in FIG. 1-F.
  • An embodiment of the invention relates to “Form F” of the crystalline phosphate salt of Compound A, having a melting point of 201±5° C., for example between 199 and 203° C., e.g. of 201.1° C.
  • In one embodiment, the invention relates to a “Form G” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, or all of the following peaks, given as angle of refraction 2-theta (θ) value, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 6.0, 12.1, 13.1, 14.0, 14.5, 15.5, 15.8, 16.3, 17.5, 18.2, 18.4, 19.3, 19.7, 20.1, 22.1, 24.3, 29.2, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form G showing an XRPD as shown in FIG. 1-G.
  • An embodiment of the invention relates to “Form G” of the crystalline phosphate salt of Compound A, having a maelting point of 180±5° C., for example between 177 and 183° C., e.g. of 179.8° C.
  • In one embodiment, the invention relates to a “Form H” of crystalline phosphate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, or al of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 6.0, 10.2, 12.1, 13.1, 14.0, 14.5, 15.5, 16.2, 16.5, 17.5, 18.2, 18.4, 19.3, 19.7, 20.1, 22.2, 24.3, 29.5, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. More preferred is the crystalline phosphate salt Form H showing an XRPD as shown in FIG. 1-H.
  • An embodiment of the invention relates to “Form H” of the crystalline phosphate salt of Compound A, having a melting point of 208±5° C., for example between 206 and 210° C., e.g. of 208.0° C.
  • In one embodiment, the invention relates to a nitrate salt of Compound A. In particular with a molar ratio of Compound A to nitrate of about 1:1, in particular in crystalline form.
  • In one special embodiment, the invention relates to a crystalline nitrate salt of Compound A having a melting point that is at least 40° C. higher than that of the free base, especially (using TG/DTA as described above) between 160 and 163° C.
  • In another special embodiment, the invention relates to a crystalline nitrate salt of Compound A, with an XRPD showing at least one, more preferably two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17 or all of the following peaks, given as angle of refraction 2-theta (θ) values, obtainable as described in the Examples, where each peak may vary by ±1 or ±0.5, in particular ±0.2 degrees: 7.4, 10.6, 12.5, 15.0, 15.7, 17.5, 18.0, 18.7, 20.4, 21.2, 22.8, 24.6, 26.5, 28.2, 28.8, 29.9, 31.0, 31.5, with the underlined peaks defining a preferred embodiment, all peaks defining a more preferred embodiment. Preferred is the nitrate salt showing an XRPD as shown in FIG. 2.
  • A specific embodiment of the invention relates to a crystalline nitrate salt of Compound A showing the XRPD characteristics above and a melting point between 180 and 163° C. using TG/DTA.
  • The compound 6,7-dihydro-5H-pyrrolo[1,2-c]imidazo-6-yl-3-fluoro-benzonitrile as free base) and especially its enantiomers, especially 4-(R)-(6,7-dihydro-6H-pyrrolo[1,2-c]imidazol-yl)-3-fluoro-benzonitrile, can be manufactured as described in published international patent application WO 2007/024945 which is incorporated by reference herein (see especially Table 2, and Chiral Resolution on page 87, F. 5).
  • “About” where used means especially ±10%, ±5% or ±3% (referring to the given numeric value, respectively), if not indicated otherwise. In each of the invention embodiments, “about” can be deleted.
  • “Prophylactically or therapeutically effective amount” means the amount of a compound that, when administered for treating or preventing a disease or disorder mentioned above or below, is sufficient to effect such treatment or prevention for the disease or disorder, prophylactic especially refers to the prevention of the onset or recurrence or ameliorating the onset or recurrence of such disease or disorder, therapeutic especially refers to the amelioration or complete suppression of one or more symptoms up to the cure of such disease or disorder. The “prophylactically or therapeutically effective amount” will vary depending on the salt(s) or salt form(s) used, the disease or disorder and its severity and the age, weight, etc., of the patient to be treated.
  • The term “pharmaceutical composition” is intended to encompass a product comprising the active ingredient(s), optionally at least one pharmaceutically acceptable excipients. The pharmaceutical compositions of the present invention encompass any composition made by admixing the active ingredient, additional active ingredient(s) and pharmaceutically acceptable excepients.
  • The term “pharmaceutical composition” is also intended to comprise a combination product, comprising a salt or salt form according to any one of claims 1 to 12, in combination with one or more other therapeutic agents (pharmaceutically active compounds) and preferably at least one pharmaceutically acceptable excipient.
  • Other therapeutic agents include at least one or two or more selected from the following groups:
      • (i) angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof,
      • (ii) HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof,
      • (iii) angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable salt thereof,
      • (iv) calcium channel blocker (CCB) or a pharmaceutically acceptable salt thereof,
      • (v) dual angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt thereof,
      • (vi) endothelin antagonist or a pharmaceutically acceptable salt thereof,
      • (vi) renin inhibitor or a pharmaceutically acceptable salt thereof,
      • (viii) diuretic or a pharmaceutically acceptable salt thereof,
      • (ix) an ApoA-I mimic;
      • (x) an anti-diabetic agent;
      • (xi) an obesity-reducing agent;
      • (xii) an aldosterone receptor blocker;
      • (xiii) an endothelin receptor blocker;
      • (xiv) a CETP inhibitor;
      • (xv) an inhibitor of Na-K-ATPase membrane pump;
      • (xvi) a beta-adrenergic receptor blocker or an alpha-adrenergic receptor blocker;
      • (xvii) a neutral endopeptidase (NEP) inhibitor; and
      • (xviii) an inotropic agent.
  • Such compounds are e.g. defined in WO 2007/024945 A1 and are included here by reference.
  • Also where not specifically mentioned, the therapeutic agent(s) may be in the free (non-salt) form or in the form of a pharmaceutically acceptable salt, respectively.
  • A compound of the present invention may be administered either simultaneously, before or after the other therapeutic agent (active ingredient), either separately by the same or different route of administration or together in the same pharmaceutical formulation.
  • Thus the combination product may comprise the salt or salt form according to the invention in one, one or more other therapeutic agents in a separate formulation, but in the form of a kit of parts for the simultaneous or chronically staggered administration, or in one fixed combination.
  • Thus, the combinations as described above can be administered to a subject via simultaneous, separate or sequential administration (use). Simultaneous administration (use) can take place in the form of one fixed combination with two or three or more active ingredients, or by simultaneously administering two or three or more compounds that are formulated independently. Sequential administration (use) preferably means administration of one (or more) compounds or active ingredients of a combination at one time point, other compounds or active ingredients at a different time point, that is, in a chronically staggered manner, preferably such that the combination shows more efficiency then the single compounds administered independently (especially showing synergism).
  • Separate administration (use) preferably means administration of the compounds or active ingredients of the combination independently of each other at different time points, preferably meaning that two, or three or more compounds are administered such that no overlap of measurable blood levels of both compounds are present in an overlapping manner (at the same time).
  • Also combinations of two or three or more of sequential, separate and simultaneous administrations are possible, preferably such that the combination compound-drugs show a joint therapeutic effect that exceeds the effect found when the combination compound-drugs are used independently at time intervals so large that no mutual effect on their therapeutic efficiency can be found, a synergistic effect being especially preferred.
  • Alternatively, the pharmaceutical compositions contain a therapeutically effective amount of a salt or salt form of Compound A of the invention as defined above or below, either alone or in a combination with one or more therapeutic agents, e.g., each at an effective therapeutic dose as reported in the art, selected from the group consisting of an antiestrogen; an antiandrogen, a gonadorelin agonist a topoisomerase I inhibitor; a topoisomerase II inhibitor a microtubule active agent an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a compound targeting/decreasing a protein or lipid kinase activity or a protein or lipid phosphatase activity, a anti-angiogenic compound; a compound which induces cell differentiation processes; monoclonal antibodies; a cyclooxygenase inhibitor; a bisphosphonate; a heparanase inhibitor a biological response modifier; an inhibitor of Ras oncogenic isoforms; a telomerase inhibitor a protease inhibitor, a matrix metalloproteinase inhibitor, a methionine aminopeptidase inhibitor; a proteasome inhibitor; agents which target, decrease or Inhibit the activity of Flt-3; an HSP90 inhibitor: antiproliferative antibodies; an HDAC inhibitor, a compound which targets, decreases or inhibits the activity/function of serine/theronine mTOR kinase; a somatostatin receptor antagonist an anti-leukemic compound; tumor cell damaging approaches; an EDG binder a ribonucleotide reductase inhibitor; an S-adenosylmethionine decarboxylase inhibitor; a monoclonal antibody of VEGF or VEGFR; photodynamic therapy; an Angiostatic steroid; an implant containing corticosteroids; an AT1 receptor antagonist; and an ACE inhibitor.
  • Additionally, the present invention provides:
      • a pharmaceutical composition or combination of the present invention for use as a medicament;
      • the use of a pharmaceutical composition or combination of the present invention for the delay of progression and/or treatment of a disorder or disease mediated by aldosterone synthase, or responsive to inhibition of aldosterone synthase, or characterized by abnormal activity or expression of aldosterone synthase.
      • the use of a pharmaceutical composition or combination of the present invention for the delay of progression and/or treatment of a disorder or disease mediated by aromatase, or responsive to inhibition of aromatase, or characterized by abnormal activity or expression of aromatase.
      • the use of a pharmaceutical composition or combination of the present invention for the delay of progression and/or treatment of a disorder or disease selected from hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, sleep apnoea, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction.
  • The salt(s) or salt form(s) of the present invention are useful as aldosterone synthase inhibitors (see e.g. WO 2007/024945 incorporated by reference herein regarding the diseases and disorders related to aldosterone synthase). In particular, the salt(s) or salt form(s) of the present invention as aldosterone synthase inhibitors are useful for treatment of a disorder or disease characterized by abnormal aldosterone synthase activity. Preferably, the salt(s) or salt form(s) of the present invention are also useful for treatment of a disorder or disease selected from hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, sleep apnoea, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction.
  • The disorder or disease to be treated with a salt or salt form according to the inventions is especially selected from hypertension (essential or resistant), primary aldosteronism congestive heart failure and acute heart failure.
  • Further diseases or disorders of specific interest are selected from the group consisting of heart failure, cachexia, acute coronary syndrome, chronic stress syndrome, Cushing's disease, Cushing's syndrome, metabolic syndrome or hypercortisolemaia. In a very preferred embodiment the disease is Cushing's disease
  • “Protic or an aprotic solvents” may be selected from aqueous or non-aqueous solvents or solvent mixtures, e.g. comprising one or more selected from water, C1-7alkanols, C1-8ketones, C1-7alkanediols, C1-7alkylnitriles, C1-7alkyl-C2-7alkanoates, with methanol, acetone, propylene glykol, ethyl acetate, or especially ethanol being especially preferred.
  • “Anti-solvent” is a solvent which when added to an existing solution of a substance reduces the solubility of the substance. In the case of the present salts, anti-solvents are especially less polar (more hydrophilic) solvents than those used for dissolving Compound A before the addition of nitric acid or phosphoric acid, e.g. organic solvents that are at least to a certain extent (e.g. at east up to 10 vol %) miscible with water.
  • Throughout this specification, where the plural forms “salts” or “salt forms” are used, this also includes a single salt or a single salt form.
    • DESCRIPTION OF THE FIGURES
  • The Figures show the XRDP of the following salts and salt forms of Compound A:
  • FIG. 1-A shows the X-ray powder diffraction pattern of the initial phosphate salt Form A.
  • FIG. 1-B shows the X-ray powder diffraction pattern of phosphate salt Form B.
  • FIG. 1-C shows the X-ray powder diffraction pattern of phosphate salt Form C.
  • FIG. 1-D shows the X-ray powder diffraction pattern of phosphate salt Form D.
  • FIG. 1-E shows the X-ray powder diffraction pattern of phosphate salt Form E.
  • FIG. 1-F shows the X-ray powder diffraction pattern of phosphate salt Form F.
  • FIG. 1-G shows the X-ray powder diffraction pattern of phosphate salt Form G.
  • FIG. 1-H shows the X-ray powder diffraction pattern of phosphate salt Form H.
  • FIG. 2 shows the X-ray powder diffraction pattern of nitrate salt.
  • FIG. 3 shows the X-ray powder diffraction pattern of chloride salt.
    •  EXAMPLES
  • The following Examples illustrate the invention without liming its scope, though they also form specific embodiments of the invention.
  • Abbreviations used:
      • IPA isopropyl alcohol
      • RH relative humidity
      • XRDP X-ray powder diffraction pattern
  • If not mentioned otherwise, al reactions are carried out at room temperature (21 to 24° C., e.g. 23° C.).
    • Example 1 Phosphate Salt of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile (Form A)
  • 2 g of free base was dissolved in 40 ml ethanol and 1 equivalent phosphoric acid was added over the course of several minutes. After addition solids were collected by filtration. The solids were dried at 22° C. under nitrogen flow. About 1.8 g were collected.
  • The molar ratio of phosphate to 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-fluoro-benzonitrile in the obtained salt is 1:1.
  • In water, the phosphate salt was soluble at the 0.1% target concentration and stable for 2 days at 50° C. The free base remained largely insoluble. It converted from a free flowing solid into an oily material within a short time after contact with water, and remained as such for the 2 day period at 50° C.
    • Hygroscopicity
  • Sorption/desorption isotherms were measured using the VTI 100 humidity microbalance (VTI Corporation, Hialeah, Fla., USA). Measurements were carried out at 25° C. Samples were dried under N2 flow at 25° C.
  • The hygroscopicity of the phosphate salt was found to be only 0% water uptake at 5% RH and 0.9% water uptake at 75% relative humidity.
    • Determination of Solubility
  • Excess solids were equilibrated in each solvent for over 24 hour at 25° C.±0.1. Concentration in supernatant was measured by gravimetry for organic solvents and by HPLC from aqueous solvents and propylene glycol.
  • The following result were obtained for the phosphate salt in comparison with the free base:
  • TABLE 1-1
    Solubility profile (mg/ml)
    Solvent Free base Phosphate salt
    pH
    1 >50 >50
    pH 6.8 28.6 >50
    Water 7.2 >50
    Ethanol >50 5.8
    Acetone >50 1.5
    Propylene glycol 34.4 1.5
    Ethyl Acetate >50 n.d.
  • This shows that the solubility of the phosphate salt is comparably low in non-aqueous solvents which are thus anti-solvents for the salt, thus making it possible to achieve good precipitation and thus good yields and good purity. On the other hand, the solubility in water is better than that for the free base which is advantageous for providing oral or parenteral formulations.
  • The melting point was determined by TG/DTA as described above and was determined to be 210.2° C.
    • Determination of the XRDP.
  • TABLE 1-2
    Parameters and device used:
    XRPD-method
    Instrument D8; Bruker (Karlsruhe, Germany)
    Irradiation CuKα (40 kV, 40 mA)
    Scan time 4 minutes (2 minutes per frame)
    Scan range 3°-40° (2 theta value)
  • The XRDP obtained for this first phosphate form (Form A) is shown in FIG. 1-A.
  • The following table shows the corresponding angle of refraction 2-Theta values (in degrees [°]) for the important peaks:
  • TABLE 1-3
    Form A
    2-Theta Peak
    (degrees) Measured
    6.0 1
    10.0 2
    12.1 3
    12.9 4
    14.0 5
    14.5 6
    15.5 7
    16.0 8
    16.3 9
    17.5 10
    18.2 11
    18.4 12
    19.7 13
    20.4 14
    22.1 15
    24.3 16
    29.2 17
    • Example 2 Nitrate Salt of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile
  • 2 g of 4-(R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile free base was dissolved in 40 ml ethanol and 1 equivalent nitric acid (same molar amounts as molar amount of free base) was added over the course of several minutes. After addition, solids were collected by filtration. The sample was dried at 21° C. to 23° C. by dry nitrogen flow. The amount recovered was 1.7 g.
  • The resulting 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile nitrate salt has a 1:1 molar ratio of base to chloride. It shows the XRPD represented in FIG. 2.
  • The hygroscopicity (measured under the conditions mentioned in Example 1) of the nitrate salt of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile was found to be 0% water uptake at 5% RH and 0.2% at 75% RH.
  • In water, the nitrate salt was soluble at the 0.1% target concentration and stable for 2 days at 50° C. The free base remained largely insoluble. It converted from a free flowing solid into an oily material within a short time after contact with water, and remained as such for the 2 day period at 50° C.
  • Solubility was determined as shown for Example 1 and the following results were obtained:
  • TABLE 2-2
    Solubility profile (mg/ml)
    Solvent Free base nitrate salt
    pH
    1 >50 >50
    pH 6.8 28.6 21.8
    Water 7.2 38.2
    Ethanol >50 4.2
    Acetone >50 2.8
    Propylene glycol 34.4 13.0
    Ethyl Acetate >50 1.5
  • Using the TG/DCA method described above, the melting point of the nitrate was determined to be between 160 and 163° C.
  • The following angle of refraction peaks (2 Theta in degrees) are found in the XRPD (using the method described in Example 1), also providing their approximate intensity:
  • TABLE 2-2
    No. 2 Theta Intensity
    1 7.4 93
    2 10.6 41
    3 12.5 23
    4 15.0 18
    5 15.7 35
    6 17.5 42
    7 18.0 64
    8 18.7 78
    9 20.4 137
    10 21.2 54
    11 22.8 45
    12 24.6 51
    13 26.5 92
    14 28.2 56
    15 28.8 33
    16 29.9 55
    17 31.0 23
    18 31.5 29
    • Example 3 Further Forms B to H of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile Phosphate Salt
  • The following salt modifications B to H were obtained as described below:
    • Preparation of Phosphate Salt Modification B
  • Form A of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazo-5-yl)-3-fluoro-benzonitrile phosphate salt was equilibrated in IPA for 72 hours at 50° C. Sample was collected by filtration and allowed to air dry. A melting temperature of form B of 209.0° C. was determined by TG/DTA.
    • Preparation of Phosphate Salt Modification C
  • 30 mg of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile phosphate salt was dissolved in water at high concentration then chilled to 6° C. Ethanol was added to precipitate form C. Sample was collected by filtration and lowed to air dry. A melting temperature of form C of 206.4° C. was determined by TG/DTA.
    • Preparation of Phosphate Salt Modification D
  • 30 mg of 4-(R)-(6,7-dihydro-6H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile phosphate salt was dissolved in methanol at 50° C. and form D is precipitated by the addition of acetone. Sample was collected by filtration and allowed to air dry. A melting temperature of form D of 210.8° C. was determined by TG/DTA.
    • Preparation of Phosphate Salt Modification E
  • 20 mg of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile free base was dissolved in 2-propanol/water solution (4:1) at room temperature. An equal molar amount of phosphoric acid was added to yield form E. Sample was collected by filtration and allowed to air dry. A melting temperature of form E of 199.2° C. was determined by TG/DTA.
    • Preparation of Phosphate Salt Modification F
  • 20 mg of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-fluoro-benzonitrile free base was dissolved in methyl i-butyl ketone at (4:1) at 50° C. An equal molar amount of phosphoric acid was added to yield form F. Sample was collected by filtration and allowed to air dry. A melting temperature of form F of 201.1° C. as determined by TG/DTA.
    • Preparation of Phosphate Salt Modification G
  • 20 mg 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile free base was dissolved in methanol (+20% water) at 5° C. An equal molar amount of phosphoric acid was added to yield form G. Sample was collected by flirtation and allowed to air dry. A melting temperate of form G of 170.8° C. was determined by TG/DTA.
    • Propitiation of Phosphate Salt Modification H
  • 20 mg 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile free base was dissolved in ethanol (+20% water) at 50° C. An equal molar amount of phosphoric add was added to yield form H after the solution is chilled to room temperature. Sample was collected by filtration and allowed to air dry. A melting temperature of form H of 208.0° C. was determined by TG/DTA.
  • The following Table 3-1 shows the angle of refraction 2-Theta values (in degrees) for the XRDPs of FIGS. 1-A to 1-H for Forms A to G in comparison to those for Form A, with characteristic peaks for each form in comparison to Form A being underlined:
  • TABLE 3-1
    A B F C D E G H
    Relative
    Measured intensity
    2-Theta (I %)
    6.0 100  6.0  6.0  6.0  6.2  6.4  6.0  6.0
    10.0 11  9.8 10.0 10.0 10.0 10.3 10.2
    12.1 14 11.8 12.1 11.9 12.4 12.1 12.1 12.1
    12.7
    12.9 21 12.9 12.9 12.9 12.9 12.9 13.1 13.1
    13.8 13.3
    14.0 10 14.0 14.0 14.0 13.3 14.0 14.0
    14.5 12 14.3 14.5 14.8 14.5 14.5 14.5
    15.5 18 15.2 15.5 15.5 15.5 15.2 15.5 15.5
    16.0 17 16.0 16.0 16.0 16.0 16.0 15.8 16.2
    16.3 20 16.3 16.6 16.3 16.6 16.8 16.3 16.5
    17.5 10 17.5 17.5 17.8 17.5 17.5 17.5 17.5
    18.2 13 18.0 18.2 18.2 18.2 18.2 18.2 18.2
    18.4 12 18.4 18.4 18.4 18.4 18.4 18.4 18.4
    19.3 19.1 19.3 19.3 19.3 19.3 19.3
    19.7 59 19.7 19.7 19.7 19.7 19.7 19.7 19.7
    20.4 20 20.1 20.1 20.1 20.2 20.1 20.1 20.1
    22.1 44 22.1 22.1 22.1 22.1 22.1 22.1 22.2
    24.3 26 24.3 24.3 24.3 24.3 24.3 24.3 24.3
    29.2 23 29.2 29.2 29.2 29.2 29.2 29.2 29.5
  • Thus it can be shown that in addition to Form A (Example 1) further polymorphs (forms) of Compound A phosphate salt can be found.
    • Comparison Example HCl Salt of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile
  • 2 g of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-y)-3-fluoro-benzonitrile free base was dissolved in 40 ml ethanol and I equivalent HCl (equal molar amount of HCl to the molar amount of the tree base) was added over the course of several minutes. Since the system did not produce crystallization, the solvent was evaporated. The solids were suspended in methyl tertbutyl ether for 2 hours at room temperature. The solids were collected by filtration. The solids were dried at 22° C. under nitrogen flow. About 1.6 g were collected.
  • The resulting 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile HCl salt has a 1:1 molar ratio of base to chloride. It showed the XRPD shown in FIG. 3.
  • The following peaks (in 2 Theta) were found in the XRPD (using the method described in Example 1):7
  • Table Comparison-1
    No. Position Intensity
    1 13.3 36
    2 14.1 51
    3 14.7 19
    4 16.2 18
    5 16.5 17
    6 16.7 24
    7 20.6 15
    8 21.0 15
    9 22.0 14
    10 23.0 25
    11 23.1 32
    12 23.5 53
    13 24.1 33
    14 24.3 37
    15 24.5 24
    16 25.7 20
    17 25.9 13
    18 26.6 52
    19 26.9 37
    20 27.6 17
    21 28.0 26
    22 28.4 40
    23 29.0 15
    24 29.7 14
  • In contrast to both the phosphate and the nitrate salts, the HCl salt showed excessive hygroscopicity, as is shown in the following table:
  • Moisture gain (%) comparison between
    forms (r.h. = relative humidity)
    r.h. % free base Nitrate Phosphate HCl
    0 0.0 0.0 0.0 0.0
    5 0.0 0.0 0.0 0.0
    25 0.1 0.1 0.1 0.5
    50 0.2 0.2 0.1 0.2
    75 0.3 0.2 0.2 0.2
    85 0.5 0.2 0.3 3.3
    95 1.0 0.2 0.8 23.6
  • It will be apparent to those sided in the art, that many modifications, both to materials, and methods, may be practiced with out departing from the purpose and interest of this invention.

Claims (13)

1. A phosphate salt of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile in a crystalline modification called form A with an XRPD showing at least one of the following peaks, given as an angle of refraction 2-theta (2θ) values, where each peak may vary by ±0.5 degrees: 12.9, 16.3, and 20.4 degrees.
2. The phosphate salt of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile in a crystalline modification called form A according to claim 1, with a molar ratio of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile to phosphate of about 1:1.
3. The phosphate salt in a crystalline modification called form A according to claim 1 having a melting point at least 50° C. higher than that of the free base.
4. The phosphate salt according to claim 1 having a melting point, using thermogravimetry/differential thermal analysis (TG/DTA), between 209 and 212° C.
5. Crystalline Form A of the phosphate salt according to claim 4 having a melting temperature of 210±0.5° C. determined by TG/DTA.
6. The phosphate salt in the crystalline modification called Form A according to claim 1 with an XRPD showing at least 4, 5, 6, 7, 8, 9 or all of the following peaks, given as angle of refraction 2-theta (θ) values, where each peak ±0.2 degrees: 6.0, 12.9, 15.5, 16.0, 16.3, 19.7, 20.4, 22.1, 24.3 and 29.2 degrees.
7. The phosphate salt in the crystalline modification called Form A according to claim 1 with an XRPD showing at least 7, 9, 11, 13, 15, 17 or all of the following peaks, where each peak may vary by ±0.2 degrees: 6.0, 10.0, 12.1, 12.9, 14.0, 14.5, 15.5, 16.0, 16.3, 17.5, 18.2, 18.4, 19.7, 20.4, 22.1, 24.3, 29.2.
8. The phosphate salt in the crystalline modification called Form A according to claim 1, wherein the two largest peaks in the XRPD diagram have a relative intensity of 1 to 0.5 to 0.7, especially of 1 to 0.55 to 0.65, more especially of 0.57 to 0.61, e.g. of 1 to 0.59 (obtainable by integration of each of the peaks in the XRPD diagrams), the larger peak being at a 2-theta (θ) value of 6.0±0.2 degrees and the smaller peak at a 2-theta (θ) value of 19.7±0.2 degrees, respectively.
9. The phosphate salt in the crystalline modification called Form A according to claim 1 showing an XRPD as shown in FIG. 1-A.
10. A process for making a phosphate salt, in crystalline form A, as defined in claim 1, of 4-(R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile, the process comprising:
(a) providing a solution of 4-(R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile in either a protic or an aprotic polar solvent;
(b) adding nitric acid or especially phosphoric acid; and
(c) isolating the formed crystalline form of a nitrate salt or especially a phosphate salt of 4-(R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile.
11. A pharmaceutical composition comprising the phosphate in crystalline Form A according to claim 1 for the treatment of Cushing's disease.
12. A method of treatment comprising administering said phosphate salt in crystalline Form A according to claim 1 to a mammal in need thereof in a therapeutically effective amount for treating Cushing's disease.
13. A pharmaceutical composition comprising a phosphate salt in crystalline form A of 4-(R)-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile and one or more pharmaceutically acceptable excipients.
US15/018,953 2012-01-17 2016-02-09 Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor Abandoned US20160176883A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/018,953 US20160176883A1 (en) 2012-01-17 2016-02-09 Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261587280P 2012-01-17 2012-01-17
PCT/US2013/021521 WO2013109514A1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
US201414370124A 2014-07-01 2014-07-01
US15/018,953 US20160176883A1 (en) 2012-01-17 2016-02-09 Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14/370,124 Continuation US9334276B2 (en) 2012-01-17 2013-01-15 Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor
PCT/US2013/021521 Continuation WO2013109514A1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor

Publications (1)

Publication Number Publication Date
US20160176883A1 true US20160176883A1 (en) 2016-06-23

Family

ID=47604250

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/370,124 Active US9334276B2 (en) 2012-01-17 2013-01-15 Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor
US15/018,953 Abandoned US20160176883A1 (en) 2012-01-17 2016-02-09 Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/370,124 Active US9334276B2 (en) 2012-01-17 2013-01-15 Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor

Country Status (40)

Country Link
US (2) US9334276B2 (en)
EP (1) EP2804863B1 (en)
JP (1) JP5749410B2 (en)
KR (2) KR20140141687A (en)
CN (1) CN104039793B (en)
AP (1) AP2014007762A0 (en)
AR (1) AR089728A1 (en)
AU (1) AU2013209952B2 (en)
BR (1) BR112014017260A8 (en)
CA (1) CA2863339C (en)
CL (1) CL2014001863A1 (en)
CO (1) CO7000775A2 (en)
CR (1) CR20140345A (en)
CU (1) CU20140086A7 (en)
CY (1) CY1117914T1 (en)
DK (1) DK2804863T3 (en)
EA (1) EA026232B1 (en)
ES (1) ES2564143T3 (en)
GT (1) GT201400155A (en)
HR (1) HRP20160178T1 (en)
HU (1) HUE026984T2 (en)
IL (1) IL233541B (en)
IN (1) IN2014DN06781A (en)
JO (1) JO3137B1 (en)
MA (1) MA35858B1 (en)
MX (1) MX2014008686A (en)
NZ (1) NZ626277A (en)
PE (1) PE20142358A1 (en)
PH (1) PH12014501638A1 (en)
PL (1) PL2804863T3 (en)
RS (1) RS54589B1 (en)
SG (1) SG11201404061YA (en)
SI (1) SI2804863T1 (en)
SM (1) SMT201600083B (en)
TN (1) TN2014000256A1 (en)
TW (1) TWI609869B (en)
UA (1) UA114803C2 (en)
UY (1) UY34576A (en)
WO (1) WO2013109514A1 (en)
ZA (1) ZA201404314B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2523731T (en) * 2010-01-14 2019-02-11 Novartis Ag Use of an adrenal hormone-modifying agent
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
TWI707682B (en) 2014-07-07 2020-10-21 瑞士商瑞科戴迪股份有限公司 Pharmaceutical dosage forms
SI3250555T1 (en) 2015-01-29 2021-08-31 Recordati Ag Process for the production of condensed imidazolo derivatives
WO2016164476A2 (en) * 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
SG11201903803UA (en) * 2016-10-27 2019-05-30 Damian Pharma Ag Aldosterone synthase inhibitor
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
SG11202010906XA (en) 2018-05-03 2020-12-30 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
WO2011088188A1 (en) * 2010-01-14 2011-07-21 Novartis Ag Use of an adrenal hormone-modifying agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5066656A (en) 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
AU668708B2 (en) 1992-01-27 1996-05-16 Janssen Pharmaceutica N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
PT1565463E (en) 2002-11-18 2008-09-10 Novartis Ag Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
JP2010513560A (en) 2006-12-18 2010-04-30 ノバルティス アーゲー 1-Substituted imidazole derivatives and their use as aldosterone synthesis inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
WO2011088188A1 (en) * 2010-01-14 2011-07-21 Novartis Ag Use of an adrenal hormone-modifying agent

Also Published As

Publication number Publication date
BR112014017260A2 (en) 2017-06-13
PH12014501638B1 (en) 2014-10-13
HK1198536A1 (en) 2015-05-15
CR20140345A (en) 2014-09-09
UY34576A (en) 2013-09-02
CL2014001863A1 (en) 2014-11-07
IN2014DN06781A (en) 2015-05-22
ZA201404314B (en) 2015-08-26
EP2804863A1 (en) 2014-11-26
TW201335161A (en) 2013-09-01
AU2013209952B2 (en) 2016-09-01
PL2804863T3 (en) 2016-06-30
SG11201404061YA (en) 2014-08-28
BR112014017260A8 (en) 2017-07-04
DK2804863T3 (en) 2016-03-07
ES2564143T8 (en) 2020-11-18
PE20142358A1 (en) 2015-01-30
SI2804863T1 (en) 2016-05-31
AP2014007762A0 (en) 2014-07-31
US20140364470A1 (en) 2014-12-11
NZ626277A (en) 2015-10-30
CU20140086A7 (en) 2014-12-26
EP2804863B1 (en) 2015-12-02
IL233541A0 (en) 2014-08-31
JO3137B1 (en) 2017-09-20
AU2013209952A1 (en) 2014-07-24
IL233541B (en) 2018-12-31
PH12014501638A1 (en) 2014-10-13
TWI609869B (en) 2018-01-01
EA201491374A1 (en) 2014-12-30
CA2863339C (en) 2021-03-23
CO7000775A2 (en) 2014-07-21
MA35858B1 (en) 2014-12-01
CY1117914T1 (en) 2017-05-17
CN104039793B (en) 2017-05-10
ES2564143T3 (en) 2016-03-18
HRP20160178T1 (en) 2016-03-25
KR20140093726A (en) 2014-07-28
US9334276B2 (en) 2016-05-10
HUE026984T2 (en) 2016-08-29
EA026232B1 (en) 2017-03-31
KR20140141687A (en) 2014-12-10
MX2014008686A (en) 2014-08-27
WO2013109514A1 (en) 2013-07-25
AR089728A1 (en) 2014-09-10
UA114803C2 (en) 2017-08-10
CN104039793A (en) 2014-09-10
TN2014000256A1 (en) 2015-09-30
JP5749410B2 (en) 2015-07-15
SMT201600083B (en) 2016-04-29
RS54589B1 (en) 2016-08-31
JP2015503627A (en) 2015-02-02
CA2863339A1 (en) 2013-07-25
GT201400155A (en) 2017-09-28

Similar Documents

Publication Publication Date Title
US20160176883A1 (en) Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor
ES2929526T3 (en) (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl) acid L-arginine crystal salt acetic acid for use in disorders associated with the S1P1 receptor
US20150344426A1 (en) Compounds and therapeutic uses thereof
JP2018024713A (en) Solid forms of epidermal growth factor receptor kinase inhibitor
UA128160C2 (en) RIP1 INHIBITING COMPOUNDS AND METHODS OF THEIR PREPARATION AND USE
JP2009502801A (en) Pyrazolopyrimidines useful as Aurora kinase inhibitors
CA2458131A1 (en) Jnk activation inhibitor
US8394821B2 (en) Activated blood coagulation factor inhibitor
TW201249858A (en) Substituted indole derivatives
US11878980B2 (en) Solid forms of TTK inhibitor
HUE028159T2 (en) Acid addition salts of risperidone and pharmaceutical compositions thereof
TW200838537A (en) Substituted quinazolines
US8895569B2 (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
HK1198536B (en) New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
US11820754B2 (en) Polymorphs of an SSAO inhibitor
US7098216B2 (en) Thiazolopyrimidines useful as TNFα inhibitors
HK40122633A (en) Jak inhibitor analogs, formulations, and uses thereof
HK1162024A (en) Acid addition salt of udenafil, preparation method thereof and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NOVARTIS PHARMACEUTICALS CORPORATION, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUTTON, PAUL ALLEN;LOESER, ERIC M;SIGNING DATES FROM 20130125 TO 20130130;REEL/FRAME:051822/0104

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMACEUTICALS CORPORATION;REEL/FRAME:051942/0673

Effective date: 20130211

AS Assignment

Owner name: RECORDATI AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS AG;REEL/FRAME:051945/0630

Effective date: 20190712